Gonal-F

Gonal-F is a prescription medication that contains the recombinant follicle‑stimulating hormone follitropin alfa. It is supplied as a sterile solution for subcutaneous injection. The product is marketed in the European Union and is used in fertility treatment protocols. As a recombinant form of FSH, Gonal‑F mimics the natural hormone to support ovarian follicle development and ovulation in women undergoing assisted reproductive care.

Gonal‑F is indicated for several reproductive‑health conditions where stimulation of follicular growth is required.

- Treatment of infertility caused by anovulation, such as in polycystic ovary syndrome, by promoting follicle growth. - Controlled ovarian stimulation for assisted reproductive technologies, including in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), to obtain multiple mature oocytes. - Ovulation induction in women with hypogonadotropic hypogonadism, helping to restore normal menstrual cycles and improve chances of conception. - Use in combination with luteinising hormone (LH) preparations for certain stimulation protocols, enhancing follicular response and luteal phase support. - Support of follicular development in donor egg cycles, facilitating the retrieval of high‑quality oocytes for donation programmes.

The safety profile of Gonal‑F includes a range of observed adverse events that vary in frequency and severity.

Common: - Injection‑site reactions such as redness, swelling, or mild pain at the administration site. - Headache or mild dizziness that may occur during the stimulation cycle. - Abdominal discomfort, bloating, or mild nausea often reported in early treatment weeks. - Mild ovarian hyperstimulation symptoms, including mild pelvic pain and transient weight gain. - Nausea or vomiting, generally mild and self‑limiting.

Serious: - Ovarian hyperstimulation syndrome (OHSS) presenting with rapid weight gain, abdominal distension, ascites, or shortness of breath, requiring medical attention. - Multiple pregnancy (twins or higher‑order gestations) increasing obstetric risk for both mother and fetuses. - Severe allergic reactions such as rash, itching, swelling, or anaphylaxis that may necessitate emergency care.

Before initiating Gonal‑F therapy, clinicians should evaluate patient history and monitor specific risk factors.

- Assess for ovarian cysts, endometriosis, or uterine abnormalities that may increase complication risk. - Perform baseline transvaginal ultrasound to determine ovarian size and follicle count prior to stimulation. - Monitor serum estradiol levels and follicular development regularly throughout the treatment cycle. - Adjust dose or discontinue therapy if signs of moderate to severe ovarian hyperstimulation appear. - Counsel patients on the increased likelihood of multiple gestations and associated obstetric risks. - Avoid use in patients with known hypersensitivity to any component of the formulation.

Gonal‑F may interact with other medications or substances that affect ovarian response or hormone metabolism.

Avoid: - Concurrent use of high‑dose gonadotropins or other FSH preparations without specialist guidance. - Use with medications that significantly increase estrogen levels, such as high‑dose oral contraceptives, during stimulation cycles. - Avoid simultaneous use of aromatase inhibitors that may alter estrogen synthesis during treatment.

Use with caution: - Co‑administration of clomiphene citrate or letrozole, which also influence follicular development. - Use alongside anticoagulants, as OHSS may increase thrombotic risk. - Concomitant use of corticosteroids, which can affect hormone levels and response to stimulation. - Use with caution when prescribing thyroid hormone replacement, as thyroid status can influence ovarian response.